Live Virtual Demo of the Harmony SHR: New Upper Body Robotic Rehabilitation System

Today Harmonic Bionics announced that they will be hosting live virtual demos of the company’s new upper-body robotic rehabilitation system, Harmony SHR. Rehabilitation professionals are invited to participate in the 15-minute demonstrations that will include an overview of the exoskeleton and how it works followed by a Q&A session with the company’s Product Director.

Harmony SHR works with a patient’s scapulohumeral rhythm (SHR) to enable natural, comprehensive therapy for both arms. When combined with Harmony SHR’s Weight Support mode, this unique shoulder design may allow for earlier initiation of post-stroke therapy.

Harmony SHR’s Preprogrammed Exercises promotes functional treatment through patient-specific movements that can enable an increased number of repetitions per session without increasing the therapist’s physical burden.  As the only rehabilitation exoskeleton with Bilateral Sync Therapy, Harmony SHR enables intent-based therapy by registering healthy arm movements and synchronizing that motion onto the stroke-affected side.

“We are excited to show Harmony SHR’s unique design and to hear feedback from the rehabilitation community on how it may help patient recovery through enabling early intervention, increasing intensity and employing patient-specific intent-based therapy,” said Harmonic Bionics CEO Christopher Prentice.  “Our aim with robotics in rehabilitation is to provide programmable, customized exercises that can help reduce the physical burden on therapists while improving the quality and efficiency of the therapy.  We believe the future of rehabilitation lies in technologies, like Harmony SHR, that increase access by facilitating more community-based therapy and home-based therapy.”

Register for the event here.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”